Communiqués Ono Pharmaceutical Co., Ltd.

Actions

4528

JP3197600004

Marché Fermé - Japan Exchange Autres places de cotation 08:00:00 10/06/2024			Varia. 5j.	Varia. 1 janv.
2 247 ^JPY	+0,47 %		+0,09 %	-10,69 %

30/04	Le japonais Ono Pharma déclare que l'achat de Deciphera pour 2,4 milliards de dollars est une "première étape" pour l'expansion mondiale	RE
29/04	Les marchés boursiers américains clôturent en hausse lundi avant les résultats et la réunion de la Fed cette semaine	MT

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Ono Pharmaceutical : Bristol Myers Squibb Announces Opdivo (nivolumab) Plus Yervoy (ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First Line Treatment for Patients with Advanced Hepatocellular Carcinoma in CheckMate 9DW Trial	05/06	PU
Ono Pharmaceutical : Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO Annual Meeting Highlighting Opdivo and Opdivo based Combinations in Earlier and Advanced Stages of Non Small Cell Lung Cancer	04/06	PU
Ono Pharmaceutical : Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma	04/06	PU
Ono Pharmaceutical : Bristol Myers Squibb Announces Updated Action Date by the U.S. Food and Drug Administration for Subcutaneous Nivolumab (nivolumab and hyaluronidase)	23/05	PU
Ono Pharmaceutical : Receives Approvals of BRAFTOVI® and MEKTOVI® for Expanded Use for Two New Indications in Japan	17/05	PU
Ono Pharmaceutical : Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial	13/05	PU
Ono Pharmaceutical : Notice regarding Differences in the Non-consolidated Financial Results between the Fiscal Year Ended March 31, 2024 and the Previous Fiscal Year	09/05	PU
Ono Pharmaceutical : Enters into a Definitive Agreement to Acquire Deciphera Pharmaceuticals	30/04	PU
PRISM BioLab, enters into a Joint Research and Licensing Agreement with Ono	26/04	AQ
Ono Pharmaceutical : Enters into a Collaboration Agreement with PRISM BioLab to Generate Novel Drug Candidates in the Oncology Area	25/04	PU
Ono Pharmaceutical : Announcement on Changes of the Board of Directors, Audit & Supervisory Board Members and Corporate Officers	05/04	PU
Ono Pharmaceutical : Announces Completion of Cancellation of Treasury Stock	29/03	PU
Ono Announces General Sponsorship for the 'Theme Weeks' as Bronze Partner, at the Expo 2025 Osaka, Kansai, Japan	28/03	AQ
Ono Enters into Comprehensive Drug Discovery Collaboration Agreement with University of Oxford	25/03	AQ
Equillium to Present at the H.C. Wainwright Autoimmune and Inflammatory Disease Conference and the LD Micro Invitational Conference	25/03	AQ
Ono Pharmaceutical : Enters into Comprehensive Drug Discovery Collaboration Agreement with University of Oxford	22/03	PU
Sibylla Biotech Enters a Strategic Drug Discovery Collaboration with Ono Pharmaceutical in Central Nervous System Disorders	15/03	AQ
Ono Pharmaceutical : Enters into a Collaboration Agreement with Sibylla Biotech to Generate Novel Drug Candidates for Neurological Disorders	14/03	PU
Ono Pharmaceutical : U.S. Food and Drug Administration Approves Opdivo® (nivolumab), in Combination with Cisplatin and Gemcitabine, for First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma	12/03	PU
Ono Pharmaceutical : Enters into a License Agreement with NEX-I to Develop and Commercialize NXI-101	06/03	PU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Ono Pharmaceutical Co., Ltd.

Actions

4528

JP3197600004

Communiqués

Filtres